ANKMJ
Ankyra Medical Journal

Ankyra Medical Journal (AnkMJ), formerly known as the Journal of Translational and Practical Medicine, regularly publishes international quality issues in the field of Medicine in the light of current information.

eISSN: 3023-655X
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Review
Current use of the faricimab in retinal diseases
Abstract
Faricimab, a novel drug in the field of ophthalmology, has garnered attention because of its promising applications in the treatment of various ocular conditions. This drug, with its dual targeting of angiopoietin-2 and vascular endothelial growth factor (VEGF), is a versatile intervention for the management of neovascular and inflammatory ocular disorders. Developed through meticulous research and clinical trials, faricimab holds promise as a multifaceted solution to longstanding challenges in ophthalmology. This review provides a comprehensive analysis of the current knowledge and clinical use of faricimab.

Keywords : Angiopoietin-2, dual mechanism, faricimab, pphthalmology, retina, vascular endothelial growth factor

Download Article


1. Leppänen VM, Saharinen P, Alitalo K. Structural basis of Tie2activation and Tie2/Tie1 heterodimerization. Proc Natl Acad SciUSA. 2017;114(17):4376-4381.
2. Duran CL, Borriello L, Karagiannis GS, Entenberg D,Oktay MH, Condeelis JS. Targeting Tie2 in the tumormicroenvironment: from angiogenesis to dissemination.Cancers. 2021;13(22):5730.
3. Sahni J, Dugel PU, Patel SS, et al. Safety and efficacy of differentdoses and regimens of faricimab vs ranibizumab in neovascularage-related macular degeneration: the AVENUE phase 2randomized clinical trial. JAMA Ophthalmol. 2020;138(9):955-963.
4. Khanani AM, Patel SS, Ferrone PJ, et al. Efficacy of every fourmonthly and quarterly dosing of faricimab vs ranibizumab inneovascular age-related macular degeneration: the STAIRWAYPhase 2 randomized clinical trial. JAMA Ophthalmol.2020;138(9):964-972.
5. Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability,and safety of intravitreal faricimab up to every 16 weeks forneovascular age-related macular degeneration (TENAYA andLUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022; 399(10326): 729-740.
6. Sahni J, Patel SS, Dugel PU, et al. Simultaneous inhibition ofangiopoietin-2 and vascular endothelial growth factor-a withfaricimab in diabetic macular edema: BOULEVARD phase 2randomized trial. Ophthalmol. 2019;126(8):1155-1170.
7. Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, andsafety of intravitreal faricimab with extended dosing up to every16 weeks in patients with diabetic macular oedema (YOSEMITEand RHINE): two randomised, double-masked, phase 3 trials.Lancet. 2022; 399(10326): 741-755.
8. Hattenbach LO, Abreu F, Arrisi P, et al. BALATON andCOMINO: phase iii randomized clinical trials of faricimab forretinal vein occlusion: study design and rationale. OphthalmolSci. 2023;3(3):100302.
9. Leung EH, Oh DJ, Alderson SE, et al. Initial real-world experiencewith faricimab in treatment-resistant neovascular age-relatedmacular degeneration. Clin Ophthalmol. 2023;17:1287-1293.
10. Hsu ST, Ponugoti A, Deaner JD, Vajzovic L. Update on retinaldrug toxicities. Curr Ophthalmol Rep. 2021;9(4):168-177.
Article available in :
Volume 2, Issue 3, 2023
Page : 114-117
https://doi.org/10.51271/JTPM-0052
Article Information
Received : 21 Kas 2023
Accepted : 25 Ara 2023
Published : 31 Ara 2023
Corresponding Author :

Burak Saatcı: Private Practice

[email protected]
Citation : Saatcı B, Çıtırık M. Current use of the faricimab in retinal diseases. J Transl Pract Med. 2023;2(3):114-117.

Read: 254
Cited: 0
Download : 64
_Footer